Key facts
- Class: synthetic 39-amino-acid peptide; dual agonist at the GIP and GLP-1 receptors, with a fatty-diacid chain that binds albumin and stretches its half-life to about five days.
- Brand names: Mounjaro (type 2 diabetes) and Zepbound (chronic weight management, obstructive sleep apnea). Same molecule, different labels.
- Approval status: FDA-approved — Mounjaro in May 2022, Zepbound in November 2023, with an added sleep-apnea indication in December 2024. Approved in the UK, EU and Australia too.
- Developer: Eli Lilly and Company.
- Route: subcutaneous injection, once weekly, prescription only.
- Evidence level: the strongest in the peptide category — multiple phase 3 randomized trials (SURPASS, SURMOUNT) with tens of thousands of participants and a completed cardiovascular outcomes trial.
- Most-reported side effects: nausea, diarrhea, vomiting, constipation, decreased appetite, injection-site reactions; boxed warning for thyroid C-cell tumors seen in rodents.
What is tirzepatide?
Tirzepatide is a synthetic 39-amino-acid peptide engineered from the backbone of glucose-dependent insulinotropic polypeptide (GIP). Chemists at Eli Lilly modified that sequence so it activates two receptors instead of one — GIP and glucagon-like peptide-1 (GLP-1) — and attached a C20 fatty diacid chain that binds circulating albumin. That single design choice is what turns a hormone with a half-life measured in minutes into a drug you inject once a week.
It reached the market under two names. Mounjaro is the type 2 diabetes label. Zepbound is the obesity label. Both contain identical tirzepatide; the split exists for regulatory and reimbursement reasons, not pharmacological ones. That distinction matters in practice, because insurers frequently cover one and refuse the other.
Tirzepatide sits inside the broader family of GLP-1 receptor agonists, but it is the first approved dual incretin agonist. Everything before it — liraglutide, dulaglutide, semaglutide — targeted GLP-1 alone.
How does tirzepatide work?
GLP-1 is an incretin hormone released from intestinal L-cells after eating. It amplifies glucose-dependent insulin secretion, suppresses glucagon, slows gastric emptying and signals satiety in the hypothalamus and brainstem — a physiology mapped in detail long before any of these drugs existed (PubMed 17928588). Because the insulin effect is glucose-dependent, it fades as blood sugar normalizes, which is why this class rarely causes hypoglycemia on its own.
GIP is the other major incretin, and for decades it was written off as therapeutically useless because GIP responsiveness looked blunted in type 2 diabetes. Tirzepatide overturned that assumption. Adding GIP agonism appears to improve insulin sensitivity in adipose tissue, influence lipid handling, and — through GIP receptors in the central nervous system — reinforce appetite suppression while possibly moderating nausea signaling. The result is an imbalanced dual agonist: it behaves as a full GIP agonist and a weaker, biased GLP-1 agonist.
Why that combination outperforms single-receptor drugs is still not fully settled. Reviews of incretin pharmacology note that receptor selectivity, signaling bias and dosing intensity all contribute, and that head-to-head trials rather than mechanism are the reliable guide (PubMed 33767808). The wider story of peptide hormones as drug targets is covered in PubMed 34067710.
Is tirzepatide FDA approved?
Yes — three times over. The FDA approved Mounjaro in May 2022 as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Zepbound followed in November 2023 for chronic weight management in adults with a BMI of 30 or above, or 27 or above with at least one weight-related comorbidity such as hypertension, dyslipidemia or obstructive sleep apnea. In December 2024 the FDA added moderate-to-severe obstructive sleep apnea in adults with obesity as a separate Zepbound indication — the first drug ever approved for that condition.
Regulators elsewhere followed: the EMA authorized Mounjaro across the EU, the MHRA in the UK, and the TGA in Australia. In every jurisdiction it is prescription-only. Both labels carry a boxed warning about thyroid C-cell tumors observed in rodent studies, and tirzepatide is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia syndrome type 2.
This puts tirzepatide in a completely different evidence tier from the research-only peptides discussed elsewhere in this library — compare it with retatrutide, which is still investigational, or with peptides sold without any approval at all.
Does tirzepatide actually work for weight loss?
SURMOUNT-1 is the trial that settled the question. It randomized 2,539 adults with obesity, or overweight plus at least one weight-related complication, and without type 2 diabetes, to weekly tirzepatide at 5, 10 or 15 mg or to placebo for 72 weeks. Mean baseline body weight was about 104.8 kg (PubMed 35658024).
Average weight change was −15.0% at 5 mg, −19.5% at 10 mg and −20.9% at 15 mg, against −3.1% on placebo. At the highest dose, 57% of participants lost at least 20% of their body weight and roughly 91% lost at least 5%. Those are effect sizes that had previously only been reported after bariatric surgery, and they arrived alongside improvements in waist circumference, blood pressure, insulin sensitivity and lipids.
SURMOUNT-1 at a glance: 2,539 adults, 72 weeks, no diabetes at baseline. Mean weight change −20.9% on 15 mg weekly versus −3.1% on placebo. Discontinuation for adverse events ranged from about 4% to 7% across the tirzepatide arms.
| Trial | Population | Duration | Comparator | Mean weight change |
|---|---|---|---|---|
| SURMOUNT-1 | 2,539 adults with obesity, no T2D | 72 weeks | Placebo (−3.1%) | −15.0% / −19.5% / −20.9% (5/10/15 mg) |
| SURMOUNT-2 | 938 adults with obesity and T2D | 72 weeks | Placebo (−3.2%) | −12.8% / −14.7% (10/15 mg) |
| SURMOUNT-4 | 670 adults after a 36-week lead-in | 52 more weeks | Placebo (+14.0% regain) | −5.5% additional loss on continued treatment |
| SURMOUNT-5 | 751 adults with obesity, no T2D | 72 weeks | Semaglutide 2.4 mg (−13.7%) | −20.2% |
| SURPASS-2 | 1,879 adults with T2D | 40 weeks | Semaglutide 1 mg (−5.7 kg) | −7.6 to −11.2 kg (5–15 mg) |
Tirzepatide in type 2 diabetes
People with type 2 diabetes consistently lose less weight on incretin drugs than people without it, and tirzepatide is no exception. SURMOUNT-2 enrolled 938 adults with both obesity and type 2 diabetes and ran the same 72-week design. Mean weight reduction was 12.8% on 10 mg and 14.7% on 15 mg, versus 3.2% on placebo (PubMed 37385275) — roughly two-thirds of the SURMOUNT-1 result.
On glycemic control, the SURPASS program tested tirzepatide against metformin monotherapy backgrounds, insulin degludec, insulin glargine and semaglutide. HbA1c reductions of around 2.0 to 2.3 percentage points were typical, with a large share of participants reaching an HbA1c below 5.7% — a threshold that is technically the non-diabetic range. Because the insulinotropic effect is glucose-dependent, hypoglycemia rates were low unless tirzepatide was combined with insulin or a sulfonylurea.
Tirzepatide vs semaglutide: the head-to-head data
Two randomized trials have compared them directly, which is rare in this field and worth more than any indirect comparison.
SURPASS-2 randomized 1,879 adults with type 2 diabetes to tirzepatide 5, 10 or 15 mg or semaglutide 1 mg for 40 weeks. Tirzepatide was noninferior and then superior on HbA1c at every dose, and produced greater weight loss — 7.6 to 11.2 kg versus 5.7 kg (PubMed 34170647).
SURMOUNT-5 answered the obesity question. It randomized 751 adults with obesity and without diabetes to maximum tolerated tirzepatide (10 or 15 mg) or maximum tolerated semaglutide (1.7 or 2.4 mg) for 72 weeks. Mean weight reduction was 20.2% with tirzepatide versus 13.7% with semaglutide, and 31.6% of the tirzepatide group lost at least a quarter of their body weight versus 16.1% on semaglutide (PubMed 40353578). Gastrointestinal side effects were common in both arms and broadly similar in character.
The honest caveat: semaglutide's 13.7% here is close to the 14.9% reported in the STEP 1 trial (PubMed 33567185), so SURMOUNT-5 did not disadvantage the comparator. But semaglutide carries a larger completed cardiovascular outcomes dataset, and higher-dose semaglutide formulations have narrowed the gap since. We break the comparison down in full in tirzepatide vs semaglutide.
Tirzepatide side effects reported in trials
The side-effect profile is dominated by the gut. A systematic review and meta-analysis of six randomized trials covering 4,586 participants quantified it: nausea in 20.4% of tirzepatide users versus 10.5% of controls, diarrhea 16.2% versus 8.6%, vomiting 9.1% versus 4.9%, decreased appetite 9.6% versus 2.9%, dyspepsia 7.1% versus 3.3%, and constipation 2.5% versus 0.9% (PubMed 37908927). In obesity trials, where doses escalate further, nausea rates ran higher still — close to 30% at the top of the range in SURMOUNT-1.
Most of these events were graded mild to moderate, appeared during dose escalation, and faded at a stable dose. They were nonetheless the leading reason people left the trials, accounting for most of the 4–7% adverse-event discontinuation rate in SURMOUNT-1.
Less common but clinically important signals include gallbladder disease (rapid weight loss of any kind raises gallstone risk), acute pancreatitis, injection-site reactions, hypersensitivity reactions, and delayed gastric emptying significant enough to complicate anesthesia and endoscopy. The label warns about acute kidney injury secondary to dehydration from vomiting or diarrhea, and about diabetic retinopathy complications in people with pre-existing retinopathy. The rodent thyroid C-cell tumor finding has not been shown to translate to humans, but it drives the boxed warning and the contraindications.
One nutritional caveat gets less attention than it deserves: at 20% weight loss, a meaningful fraction of the loss is lean mass. Trial protocols paired the drug with dietary counseling and activity for that reason.
What happens when you stop tirzepatide?
SURMOUNT-4 was built to answer exactly this. All 670 participants took open-label tirzepatide for 36 weeks and lost an average of 20.9%. They were then randomized to continue the drug or switch to placebo for a further 52 weeks. The continued group lost another 5.5%. The placebo group regained 14.0% of body weight (PubMed 38078870). From original baseline, that is roughly −25.3% versus −9.9% at the end of the trial.
Follow-up analyses showed that the improvements in waist circumference, blood pressure, non-HDL cholesterol, glycemic measures and insulin resistance reversed in proportion to how much weight came back. The same pattern appeared after semaglutide withdrawal, where participants regained about two-thirds of their prior weight loss within a year (PubMed 35441470).
The practical reading is that tirzepatide behaves like a treatment for a chronic condition rather than a course of therapy with a finish line. Stopping does not reset anything; it removes an ongoing pharmacological effect on appetite regulation.
Sleep apnea and cardiovascular outcomes
The SURMOUNT-OSA program randomized adults with moderate-to-severe obstructive sleep apnea and obesity — one trial in people not using positive airway pressure, one in people already on it — to tirzepatide or placebo for 52 weeks. The apnea-hypopnea index fell by roughly 25 to 29 events per hour with tirzepatide versus about 5 with placebo, alongside improvements in hypoxic burden, blood pressure, inflammatory markers and patient-reported sleep quality (PubMed 38912654). That result produced the December 2024 label expansion.
Cardiovascular outcomes arrived later. SURPASS-CVOT randomized 13,299 adults with type 2 diabetes and established atherosclerotic cardiovascular disease to tirzepatide or dulaglutide, an older GLP-1 agonist with proven cardiovascular benefit, and followed them for a median of about four years. The composite of cardiovascular death, myocardial infarction or stroke occurred in 12.2% on tirzepatide versus 13.1% on dulaglutide — hazard ratio 0.92, meeting noninferiority but not superiority (PubMed 41406444). Death from any cause was nominally lower with tirzepatide, and metabolic and renal measures favored it, but gastrointestinal adverse events were more frequent.
The takeaway is precise and worth stating carefully: tirzepatide is at least as cardioprotective as an established GLP-1 agonist in this population. It has not been shown to be superior on hard cardiovascular endpoints.
How long does tirzepatide take to work?
Appetite changes typically show up within the first one or two weekly injections, and glucose starts moving in the first weeks. Weight loss is much slower and roughly linear for a long time: SURMOUNT-1 participants were still losing weight at week 72, with the curve beginning to flatten somewhere around months 15 to 18. Trial protocols escalated the dose over roughly 20 weeks before reaching the maintenance level, so any judgment made at week 4 or week 8 measures the titration phase, not the drug's full effect.
Response varies enormously between individuals. In SURMOUNT-1, some participants lost more than 30% of body weight while others lost under 5% on the same dose. Tracking weight, appetite, side effects and injection dates against your titration schedule is the only way to see which of those curves you are on — that is the exact use case PepMate was built for, and we cover the method in how to track peptides.
Cost, access and the gray market
Tirzepatide is expensive. US list prices for Mounjaro and Zepbound have run above $1,000 per month, and coverage is inconsistent — many commercial plans cover the diabetes indication but exclude obesity treatment outright, and US Medicare Part D has historically been barred from covering drugs prescribed purely for weight loss. Manufacturer savings programs and direct-to-consumer vial channels have brought self-pay prices down substantially for some doses, but affordability, not efficacy, remains the main barrier for most people.
That gap created a large gray market. During the 2023–2024 shortage, US compounding pharmacies were permitted to produce tirzepatide copies; after the FDA declared the shortage resolved in late 2024, that permission ended and mass compounding was wound down through 2025. What persists is unregulated vials sold online labeled as research chemicals or not for human consumption. These are not approved drugs, are not subject to any pharmaceutical quality control, and independent testing of similar products has repeatedly found inconsistent content and purity. PepMate does not recommend or link to any source of peptides. See are peptides legal for how the regulatory lines are actually drawn.
For context on where tirzepatide sits among the alternatives, see our overviews of peptides studied for weight loss, the newer triple agonist retatrutide (PubMed 37366315), and the semaglutide brands Wegovy and Ozempic. Background on how peptide hormones become drugs is summarized in PubMed 40234176 and PubMed 31050435.
Frequently asked questions
Is tirzepatide the same as Mounjaro and Zepbound?
Yes. Tirzepatide is the active molecule; Mounjaro and Zepbound are two Eli Lilly brand names for it. Mounjaro is approved for type 2 diabetes, Zepbound for chronic weight management and for moderate-to-severe obstructive sleep apnea in adults with obesity. Same peptide, different labels, different approved indications and often different insurance coverage.
How much weight do people lose on tirzepatide?
In SURMOUNT-1, adults with obesity and without diabetes lost an average of 15.0%, 19.5% and 20.9% of body weight on the 5 mg, 10 mg and 15 mg weekly doses over 72 weeks, versus 3.1% on placebo. In SURMOUNT-2, participants who also had type 2 diabetes lost less: 12.8% and 14.7%. Individual results vary widely around those averages.
Is tirzepatide better than semaglutide for weight loss?
In the head-to-head SURMOUNT-5 trial, tirzepatide produced 20.2% average weight loss at 72 weeks versus 13.7% with semaglutide 2.4 mg. SURPASS-2 found tirzepatide also lowered HbA1c and body weight more than semaglutide 1 mg in type 2 diabetes. Semaglutide has the longer cardiovascular outcomes record, so better depends on the goal.
What are the most common tirzepatide side effects?
Gastrointestinal effects dominate. A meta-analysis of six randomized trials reported nausea in 20.4% of tirzepatide users versus 10.5% of controls, diarrhea in 16.2% versus 8.6%, vomiting in 9.1% versus 4.9%, and constipation in 2.5% versus 0.9%. Most events were mild to moderate and clustered around dose increases. Gallbladder problems, pancreatitis and injection-site reactions are less common.
Do you regain weight after stopping tirzepatide?
Usually, yes. In SURMOUNT-4, participants who had already lost about 20.9% during a 36-week lead-in were randomized to continue or switch to placebo. Over the next 52 weeks the placebo group regained 14.0% of body weight while the continued group lost a further 5.5%. Cardiometabolic improvements reversed in proportion to the weight regained.
Is tirzepatide legal to buy without a prescription?
No. Tirzepatide is a prescription-only drug in the United States, the UK, the EU and Australia. Vials sold online as research chemicals or not for human consumption are unapproved, unregulated and have been found to vary in purity and content. Since the FDA declared the tirzepatide shortage resolved in late 2024, routine compounded copies are also no longer permitted.
How long does tirzepatide take to work?
Appetite suppression often appears within the first one to two weekly injections, and blood glucose starts falling in the first weeks. Weight loss builds gradually: SURMOUNT-1 participants were still losing weight at 72 weeks, with the curve flattening around months 15 to 18. Trials titrate the dose upward over roughly 20 weeks, so early results underestimate the eventual effect.
Does tirzepatide protect the heart?
SURPASS-CVOT randomized 13,299 adults with type 2 diabetes and atherosclerotic cardiovascular disease to tirzepatide or dulaglutide. Cardiovascular death, heart attack or stroke occurred in 12.2% versus 13.1%, a hazard ratio of 0.92 that met noninferiority but not superiority. Tirzepatide is therefore at least as protective as an established GLP-1 agonist, not proven better.
Can you take tirzepatide if you do not have diabetes?
Zepbound is approved for chronic weight management in adults with a BMI of 30 or more, or 27 or more with at least one weight-related condition, regardless of diabetes status. SURMOUNT-1 enrolled only participants without type 2 diabetes. Eligibility is a clinical decision made by a licensed prescriber, not something to self-determine.
Sources
Every claim above traces to peer-reviewed literature indexed on PubMed:
- Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1) — PubMed 35658024
- Tirzepatide once weekly for the treatment of obesity in people with type 2 diabetes (SURMOUNT-2) — PubMed 37385275
- Continued Treatment With Tirzepatide for Maintenance of Weight Reduction in Adults With Obesity: The SURMOUNT-4 Randomized Clinical Trial — PubMed 38078870
- Tirzepatide as Compared with Semaglutide for the Treatment of Obesity (SURMOUNT-5) — PubMed 40353578
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2) — PubMed 34170647
- Cardiovascular Outcomes with Tirzepatide versus Dulaglutide in Type 2 Diabetes (SURPASS-CVOT) — PubMed 41406444
- Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity — PubMed 38912654
- Tirzepatide-Induced Gastrointestinal Manifestations: A Systematic Review and Meta-Analysis — PubMed 37908927
- Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP 1) — PubMed 33567185
- Weight regain and cardiometabolic effects after withdrawal of semaglutide — PubMed 35441470
- GLP-1 receptor agonists: an updated review of head-to-head clinical studies — PubMed 33767808
- The physiology of glucagon-like peptide 1 — PubMed 17928588
- The Role of Peptide Hormones Discovered in the 21st Century in the Regulation of Appetite and Metabolism — PubMed 34067710
- Triple-Hormone-Receptor Agonist Retatrutide for Obesity — PubMed 37366315
- Understanding peptide hormones: from precursor proteins to biological function — PubMed 40234176
- Glucagon-Like Peptide-1 Receptor Agonists and Strategies To Improve Their Efficiency — PubMed 31050435